Cutaneous Melanoma of the Extremity

subtype

Identifier: CI-CAN-00002483
Entity page: /cancer/cutaneous-melanoma-of-the-extremity ↗
Edges: 48

Neighbours: 15 drugs10 trials
Drawn: 25 of 25 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Cutaneous Melanoma of the Extremity investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 17show all (up to 200)
→ investigated in trials for	Nivolumabmonoclonal antibody 8 trials (6 active) · roll-up of the cancer and its descendants	—	—	Cutaneous Melanoma of the Extremity	8	Observed	clinicaltrials	graph →
→ investigated in trials for	Ipilimumab

Cutaneous Melanoma of the Extremity studied in …STUDIED_INderived10 of 31show all (up to 200)
→ studied in	NCT07576725Phase 2 · not yet recruiting Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial · condition mapped CURATED_BROADER · 31 trials mapped (17 active)	—	—	Acral Lentiginous Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04462406Phase 2 · active not recruiting Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial · condition mapped CURATED_BROADER · 31 trials mapped (17 active)	—	—	Acral Lentiginous Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04511013Phase 2 · recruiting A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases · condition mapped ONTOLOGY_EXACT · 31 trials mapped (17 active)	—	—	Acral Lentiginous Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT00937937Phase 2 · active not recruiting Dinaciclib in Treating Patients With Stage IV Melanoma · condition mapped ONTOLOGY_EXACT · 31 trials mapped (17 active)	—	—	Acral Lentiginous Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03025256Phase 1 · active not recruiting Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease · condition mapped ONTOLOGY_EXACT · 31 trials mapped (17 active)	—	—	Acral Lentiginous Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03698019Phase 2 · active not recruiting A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma · condition mapped ONTOLOGY_EXACT · 31 trials mapped (17 active)	—	—	Acral Lentiginous Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05098210Phase 1 · recruiting Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer · condition mapped CURATED_BROADER · 31 trials mapped (17 active)	—	—	Acral Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05628883Phase 1 · completed Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma · condition mapped ONTOLOGY_EXACT · 31 trials mapped (17 active)	—	—	Acral Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04119024Phase 1 · recruiting Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors · condition mapped ONTOLOGY_EXACT · 31 trials mapped (17 active)	—	—	Acral Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07347444Phase 2 · not yet recruiting Iparomlimab and Tuvoraleimab Injection in Combination With Bevacizumab, Albumin-bound Paclitaxel, and Carboplatin as First- or Second-line Treatment for Patients With Advanced Acral and Mucosal Melanoma · condition mapped ONTOLOGY_EXACT · 31 trials mapped (17 active)	—	—	Acral Melanoma	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Strongest chains